Intec Pharma - Bolstering the case for AP-CDLD
Intec Pharma recently released the results from two pharmacokinetic (PK) studies of AP-CDLD (n=18 and n=30). The data showed trends towards lower...
111 Views
Intec Pharma - Phase III more than half the way there
The year 2017 was marked by steady progress in Intec’s development program of AP-CDLD for the treatment of Parkinson’s disease (PD). The drug is a...
155 Views
Intec Pharma - Ongoing AP clinical trials
Intec Pharma’s clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP), are ongoing. The company...
153 Views
AP-CDB/THC performs in Phase I
Intec Pharma announced on 3 August 2017 that it had completed the Phase I clinical trial of AP-CBD/THC in 21 healthy volunteers. AP-CBD/THC is a...
147 Views
Getting closer to data
Intec is moving closer to data from its clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP)....
135 Views
No more insights